Amdocs faces a new securities fraud investigation after a T-Mobile contract dispute triggered a 30% stock price drop and a significant reduction in fiscal 2027 earnings projections.
Amdocs guided fiscal 2027 revenue growth down 14.3% to 17.9% and EPS down 26% to 30% on November 3, 2026, citing a contractual dispute with T-Mobile, a major customer. The stock collapsed $18.77 (30.07%) to $43.66 on November 4, and the newly announced Pomerantz securities-fraud investigation adds litigation overhang, supporting further downside pressure.
Pomerantz LLP is investigating whether Amdocs and certain officers or directors engaged in securities fraud or other unlawful business practices, after the company sharply cut its fiscal 2027 outlook on November 3, 2026, citing a contractual dispute with T-Mobile.
Amdocs shares dropped $18.77 per share, or 30.07%, closing at $43.66 on November 4, 2026, the day after the weak fiscal 2027 guidance was issued.
Pomerantz LLP has launched a securities fraud investigation into Amdocs Limited following a sharp downward revision of its fiscal 2027 guidance. The company cited a major contractual dispute with T-Mobile as the primary driver for the projected 14.3% to 17.9% revenue decline. Amdocs shares plummeted 30.07% on November 4, 2026, as investors reacted to the weakened outlook and potential litigation risks.
Pomerantz LLP is investigating whether Amdocs and certain officers or directors engaged in securities fraud or other unlawful business practices, after the company sharply cut its fiscal 2027 outlook on November 3, 2026, citing a contractual dispute with T-Mobile.
Amdocs shares dropped $18.77 per share, or 30.07%, closing at $43.66 on November 4, 2026, the day after the weak fiscal 2027 guidance was issued.